Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $700,000
- Closes
- Jan 11, 2027 (in 87 days)
Similar opportunities open now
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2029
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 25 days)Up to $150K
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 23, 2026 (in 38 days)
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Mar 2029
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 25 days)Up to $300K
Classification and identifiers
- Solicitation number
- RFA-CA-27-005
- Assistance listing (CFDA)
- 93.394
Amount
$700,000
Who can apply
Private colleges and universities and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations…
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: ...